Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Humanigen, Inc.

https://www.humanigen.com/

Latest From Humanigen, Inc.

Finance Watch: UroGen Accesses Cash After Phase III Bladder Cancer Success

Public Company Edition: UroGen raised $120m in a private placement of ordinary shares. Also, Verrica entered into a debt financing for up to $125m upon approval of Ycanth for molluscum contagiosum and job cuts were announced by Homology, Mersana, Infinity and others.

Financing Restructuring

InflaRx Looks Ahead To Late 2023 Commercial Sales For COVID-19 Antibody

The price will be more expensive than prior COVID-19 antibodies, reflecting its target to critically ill patients who are hospitalized.

Approvals Coronavirus COVID-19

Humanigen Isn’t Throwing In The Towel On Lenzilumab For COVID-19 Just Yet

The company is assessing a potential path forward in COVID-19 for the drug and is in talks with platform study groups after a Phase III study did not show statistical significance, but still showed activity.

Coronavirus COVID-19 Biologics

Publisher’s Spotlight: Citeline Awards Honor R&D Excellence

Pharma Intelligence congratulates the winners of the 2021 Citeline Awards. 

Clinical Trials Diversity & Inclusion
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • KaloBios Pharmaceuticals, Inc.
    • Humanigen Australia Pty Ltd
UsernamePublicRestriction

Register